title: Bayer's Xarelto® is approved in South Africa across five additional indications.
mesh_terms: D001281:Atrial Fibrillation / Q000188:drug therapy*; D017277:Drug Approval; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use*; D000069552:Rivaroxaban; D013019:South Africa; D013876:Thiophenes / Q000627:therapeutic use*; D013923:Thromboembolism / Q000188:drug therapy*
chemical_list: D009025:Morpholines; D013876:Thiophenes; D000069552:Rivaroxaban